What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Gene
His primary scientific interests are in Cancer research, Angiogenesis, Internal medicine, Molecular biology and Immunology.
His Cancer research study combines topics in areas such as Mutation, Carcinogenesis, Cancer and Vascular endothelial growth factor A.
His biological study spans a wide range of topics, including Tumor progression, Biochemistry and Metronomic Chemotherapy.
The concepts of his Internal medicine study are interwoven with issues in Endocrinology, Progeria, Oncology and Progerin.
His study in Molecular biology is interdisciplinary in nature, drawing from both Enhancer, Transcription factor, Gene expression, Zebrafish and Regulation of gene expression.
His Gene expression research includes themes of Myeloid, Myelopoiesis and Danio.
His most cited work include:
- The DNA binding subunit of NF-κB is identical to factor KBF1 and homologous to the rel oncogene product (652 citations)
- A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors (541 citations)
- Intraembryonic hematopoietic cell migration during vertebrate development (515 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of study are Internal medicine, Cancer research, Pathology, Glioma and Oncology.
His studies in Internal medicine integrate themes in fields like Gastroenterology, Endocrinology, Surgery and Cardiology.
His Surgery study combines topics from a wide range of disciplines, such as Neurology and Pediatrics.
While the research belongs to areas of Cancer research, Mark W. Kieran spends his time largely on the problem of Cancer, intersecting his research to questions surrounding Pharmacology.
His studies deal with areas such as Medulloblastoma, Progressive disease, Regimen and Neurofibromatosis as well as Oncology.
His Disease research incorporates elements of Clinical trial and Progeria.
He most often published in these fields:
- Internal medicine (29.66%)
- Cancer research (31.62%)
- Pathology (21.08%)
What were the highlights of his more recent work (between 2016-2021)?
- Cancer research (31.62%)
- Internal medicine (29.66%)
- Oncology (16.18%)
In recent papers he was focusing on the following fields of study:
Cancer research, Internal medicine, Oncology, Glioma and Cancer are his primary areas of study.
His specific area of interest is Cancer research, where he studies Low-Grade Glioma.
His Internal medicine research is multidisciplinary, relying on both Gastroenterology and Dabrafenib.
His Oncology research focuses on subjects like Neurofibromatosis, which are linked to Astrocytoma.
His work deals with themes such as Clinical trial, Pathology and Microglia, which intersect with Glioma.
His Cancer research is multidisciplinary, incorporating elements of Angiogenesis, Macrophage, Gene and Family medicine.
Between 2016 and 2021, his most popular works were:
- Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq (206 citations)
- Challenges to curing primary brain tumours (159 citations)
- Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas (113 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
His primary areas of investigation include Cancer research, Internal medicine, Clinical trial, Cohort and Proinflammatory cytokine.
His primary area of study in Cancer research is in the field of Melanoma.
The various areas that he examines in his Internal medicine study include Gastroenterology and Oncology.
His Clinical trial research integrates issues from Young adult, Medulloblastoma, Dabrafenib, Glioma and Confounding.
Mark W. Kieran focuses mostly in the field of Cohort, narrowing it down to topics relating to Cohort study and, in certain cases, Hazard ratio, Cause of death and Mortality rate.
Mark W. Kieran interconnects BRAF V600E and Pathology in the investigation of issues within Chemotherapy.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
